Scandion Oncolgy har i dag meddelt, at de udvider deres kliniske CORIST studier til Tyskland og Spanien.

The Federal Institute for Drugs and Medical Devices (BfArN), det spanske Agency of Medicines and Medical Devices (AEMPS) samt de lokale tyske og spanske etiske komiteer har givet tilladelse til de kliniske test. Scandion Oncology forventer derfor snarligt at opstarte de kliniske test i Tyskland og Spanien.

Resultaterne fra studierne forventes fortsat at komme i løbet af Q2/Q3 i indeværende år. I forbindelse med denne nyhed udtaler Scandion Oncology’s CEO, Bo Rode Hansen:

We are pleased to expand the CORIST-trial and further enhance our capabilities to conduct clinical trials internationally. It is a corner stone of our strategy to build the capacity to carry through full clinical development. This will allow us to pursue co-development partnerships or independently develop our molecules depending on how we can best create maximum value for patients, caregivers, the company and its owners.